Together, this suggests that an ERK-MSK/RSK-CBP/p300-ETS axis, acting through multiple points, synergizes to suppress NE differentiation, providing biological rationale for the absence of MAPK pathway activation in SCLC (Figure 7a). This evidence concerns the gene RPS6KA3 and small cell lung carcinoma.